Entering text into the input field will update the search result below

Q3 Biotech Catalyst Watch: Phase 3 Data Releases (Part 2)

Jul. 06, 2017 11:48 AM ETABBV, ACRX, ALKS, ALNY, VTRS, NKTR, PRTK, RDHL, SAGE, TBPH, IBB, XBI11 Comments
Slingshot Insights profile picture
Slingshot Insights


  • 2017’s third quarter holds important data and regulatory releases with significant potential impacts on pharmaceutical share prices.
  • In the next few weeks, we will look at PDUFAs investors should have on their radar in Q3. Phase 2 data was covered in my previous article.
  • Investors informed on major market events can capitalize on their diligence. This article covers key Phase 3 data releases from ABBV, ACRX, ALNY, NKTR, PRTK, RDHL, SAGE, and TPBH.

The third quarter of 2017 is packed with an abundance of Phase 2, Phase 3, and PDUFA data releases about which diligent pharma investors should know. Some results expected in the third quarter, like those of Alkermes (ALKS) schizophrenia drug ALKS-3831, have already posted results. Over the coming weeks we will round out the overview with regulatory catalysts coming in Q3 (we covered Phase 2 data last week here) with the goal being to help investors develop a succinct summary of the Q3 landscape. Investors should care because these events will influence stock prices heavily and could provide a profitable opportunity.

Let’s take a look at upcoming Phase 3 data releases from 8 pharma companies: AbbVie Inc (NYSE:ABBV), AcelRx Pharmaceuticals Inc (NASDAQ:ACRX), Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), Nektar Therapeutics (NASDAQ: NKTR), Paratek Pharmaceuticals Inc (NASDAQ: PRTK), RedHill Biopharma Ltd (NASDAQ: RDHL), SAGE Therapeutics Inc (NASDAQ: SAGE), and Theravance Biopharma Inc (NASDAQ: TBPH).

Phase 3 Data Coming Q3

ABBV: Using Upadacitinib (ABT-494) to Treat Rheumatoid Arthritis

ABBV expects Phase 3 data from its SELECT-BEYOND Phase 3 trial evaluating its JAK1 selective inhibitor Upadacitinib (ABT-494) in rheumatoid arthritis [RA] sometime this summer. Importantly, a second Phase 3 trial for Upadacitinib (SELECT-NEXT) in rheumatoid arthritis posted positive results June 7, 2017. Promisingly, the trial met all of its primary and ranked secondary endpoints with statistical significance in both the 15mg and 30mg dosing groups. Investors should be dialed in to the outcome of this potential standout drug because it could have a big impact on share prices. There are about 1.5 million people in the U.S. with RA, and although there are already a number of effective drugs for the disease (Rituxan, Actemra, Humira, etc), ABT-494 is also in Phase 2 trials for ulcerative colitis, Crohn’s diseases, and atopic dermatitis. This broad effectiveness could make the drug ABBV’s next Humira. More info on the rest of ABBV’s gargantuan pipeline

This article was written by

Slingshot Insights profile picture
Slingshot Insights is the first crowdfunded expert network and due diligence community. Members use our suite of tools to cut through the noise and Become the Smart Money.  We provide you affordable access to Experts and Management Teams so that you can make informed investment decisions.  By grouping investors around project ideas they care about, we pass along significant savings without compromising on quality.

Analyst’s Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.